Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Berlex Issues Betaseron Liver Testing Reminder Due To Increased MS Safety Focus

This article was originally published in The Pink Sheet Daily

Executive Summary

“Dear Health Care Professional” letter is sent to 7,000 physicians reminding them that liver function testing is recommended at one, three and six months following initiation of Betaseron for MS treatment.

You may also be interested in...

Biogen Idec Adds Liver Warning To Multiple Sclerosis Therapy Avonex

Interferon beta product joins Serono/Pfizer's Rebif with warning reflecting postmarketing experiences. Berlex' Betaseron does not have a warning but recommends testing. Coming on the heels of the Tysabri withdrawal, the labeling change is the second recent setback for Biogen Idec's multiple sclerosis franchise.

Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan

One fatal, confirmed case of progressive multifocal leukoencephalopathy and one suspected case prompt withdrawal of multiple sclerosis product; risk/benefit ratio needs to be reestablished, companies say. Return to market would not be unprecedented, but Tysabri’s withdrawal sharpens focus on FDA's drug safety oversight.

When It Comes To A COVID-19 Vaccine For Kids, It Will Be Awhile

US FDA will be cautious about development of a COVID-19 vaccine for children, Commissioner Hahn says at the Financial Times US Pharma And Biotech Summit.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts